Results from a trial in patients with skeletal-related events linked to metastatic breast cancer demonstrate a higher rate of success controlling pain.
The trial featured over 2,000 patients over 73 weeks. Every four weeks, one arm received 120 mg of subcutaneous denosumab (Prolia), the other arm received 4 mg IV zoledronic acid (Zometa).
Throughout the trial, researchers used the Brief Pain Inventory to assess pain levels.
Compared to patients in the zoledronic acid arm, patients in the denosumab arm who were either pain-free or with only mild pain experienced had a significantly longer median time to development of moderate/severe pain: 176 days vs. 295 days.
CANCER TYPE(S)
Metastatic breast cancer
TREATMENT TYPE(S)
Pain control
WHERE WAS THIS STUDY PUBLISHED?
This study was presented as an abstract at the 2010 ASCO Breast Cancer Symposium. It has not yet been published in a peer-reviewed scientific journal; until then its findings should be considered preliminary only.
Source
"Pain in patients (pts) with metastatic breast cancer: Results from a phase III trial of denosumab versus zoledronic acid (ZA)" #265.
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
